Undiagnosed Liver Fibrosis in Europe: Drivers and the Importance of Early Detection

A multinational European cohort study known as the LiverScreen project has identified a high prevalence of undiagnosed liver fibrosis within the general population in Europe. The research, published in The Lancet on April 11, 2026, indicates that this condition often remains undetected despite its potential for progression.

Liver fibrosis involves the scarring of liver tissue, which can occur as a result of chronic inflammation. According to the study, the primary drivers of this condition in the general European population are metabolic factors and alcohol consumption.

Drivers of Liver Fibrosis

The findings highlight that undiagnosed fibrosis is closely linked to steatotic liver disease. This form of liver disease is driven by metabolic risk factors and/or high-risk alcohol use.

Metabolic factors typically include conditions associated with obesity and metabolic syndrome, which contribute to the accumulation of fat in the liver and subsequent scarring.

The Importance of Early Detection

The researchers emphasize that early detection of liver fibrosis is pivotal for patient outcomes. Identifying the condition in its early stages allows for the implementation of personalized interventions.

early detection is pivotal as it could allow personalised interventions that can prevent progression to cirrhosis and complications

The Lancet

Without early identification and intervention, liver fibrosis can progress to cirrhosis, a more advanced stage of liver scarring that can lead to severe complications and liver failure.

Clinical Context and Diagnostics

The prevalence of these undiagnosed cases underscores a gap in current screening practices for the general population. The study suggests that metabolic-associated liver diseases require a focus on noninvasive diagnostics to identify at-risk individuals.

Personalized treatments are an emerging area of focus for managing metabolic associated liver diseases, aiming to tailor interventions to the specific risk factors—whether metabolic or alcohol-related—driving the fibrosis in an individual patient.

By shifting toward earlier detection, healthcare providers may be able to halt the progression of liver damage before it reaches a critical or irreversible stage.